 Ranbaxy Laboratories Limited (RLL) has received final approval from the U.S.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>The approvals are for oral solution for allergy and children

Ranbaxy set to market drugs in the US

Also Read

Cipla Q4 net jumps 42.8% y-o-y

India to be a $637-bn retail market by 2015

Force India ties up for zero emission bikes

Haryana inks MoU with Reliance Insurance

Audi plans to sell 1,200 units India in 2008

Explore News